Tae‐You Kim

17.5k total citations · 3 hit papers
189 papers, 7.6k citations indexed

About

Tae‐You Kim is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Tae‐You Kim has authored 189 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Oncology, 71 papers in Pulmonary and Respiratory Medicine and 55 papers in Molecular Biology. Recurrent topics in Tae‐You Kim's work include Colorectal Cancer Treatments and Studies (47 papers), Lung Cancer Treatments and Mutations (32 papers) and Hepatocellular Carcinoma Treatment and Prognosis (28 papers). Tae‐You Kim is often cited by papers focused on Colorectal Cancer Treatments and Studies (47 papers), Lung Cancer Treatments and Mutations (32 papers) and Hepatocellular Carcinoma Treatment and Prognosis (28 papers). Tae‐You Kim collaborates with scholars based in South Korea, United States and Ethiopia. Tae‐You Kim's co-authors include Seock‐Ah Im, Yung‐Jue Bang, Sae‐Won Han, Do‐Youn Oh, Dae Seog Heo, Dong‐Wan Kim, Kyung-Hun Lee, Se‐Hoon Lee, Jee Hyun Kim and Masatoshi Kudo and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Tae‐You Kim

186 papers receiving 7.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

2021 891 citations Masafumi Ikeda, Tae‐You Kim et al. Journal of Hepatology profile →
Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

2005 656 citations Sae‐Won Han, Tae‐You Kim et al. profile →
IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).

2021 229 citations Masafumi Ikeda, Tae‐You Kim et al. profile →

Peers

Tae‐You Kim

ONCOL

PRM

HEPAT

Mario Scartozzi Italy

Christopher Stroh Germany

Alain Hendlisz Belgium

Jianming Xu China

Edwin P. Hui Hong Kong

Robert R. McWilliams United States

Chiun Hsu Taiwan

Lorenza Rimassa Italy

Hans Prenen Belgium

Alessandro Rizzo Italy

Mario Scartozzi Italy

Tae‐You Kim

3.7k ×0.9

ONCOL

2.1k ×0.8

PRM

1.7k ×0.8

953 ×0.6

HEPAT

1.5k ×1.0

Citations per year, relative to Tae‐You Kim Tae‐You Kim (= 1×) peers Mario Scartozzi

Countries citing papers authored by Tae‐You Kim

Since Specialization

Citations

This map shows the geographic impact of Tae‐You Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tae‐You Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tae‐You Kim more than expected).

Fields of papers citing papers by Tae‐You Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tae‐You Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tae‐You Kim. The network helps show where Tae‐You Kim may publish in the future.

Co-authorship network of co-authors of Tae‐You Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Tae‐You Kim. A scholar is included among the top collaborators of Tae‐You Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tae‐You Kim. Tae‐You Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lee, Keun‐Wook, Sae‐Won Han, Tae Won Kim, et al.. (2023). A Phase 1b/2a Study of GC1118 with 5-Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in Patients with Recurrent or Metastatic Colorectal Cancer. Cancer Research and Treatment. 56(2). 590–601. 1 indexed citations

Park, Hye Eun, Jung Ho Kim, Xianyu Wen, et al.. (2019). Whole-Slide Image Analysis Reveals Quantitative Landscape of Tumor–Immune Microenvironment in Colorectal Cancers. Clinical Cancer Research. 26(4). 870–881. 46 indexed citations

Yau, Thomas, Chiun Hsu, Tae‐You Kim, et al.. (2019). Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. Journal of Hepatology. 71(3). 543–552. 187 indexed citations

Lim, Yoojoo, Sae‐Won Han, Jeong Hee Yoon, et al.. (2015). Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal Cancer. PLoS ONE. 10(12). e0145004–e0145004. 17 indexed citations

Lee, Kyung-Hun, Kyoung Bun Lee, Tae‐Yong Kim, et al.. (2015). Clinical and pathological significance of ROS1 expression in intrahepatic cholangiocarcinoma. BMC Cancer. 15(1). 721–721. 20 indexed citations

Cha, Yongjun, Sae‐Won Han, Hyesil Seol, et al.. (2014). Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer.. PubMed. 34(8). 4275–80. 8 indexed citations

Min, Ahrum, Seock‐Ah Im, Young‐Kwang Yoon, et al.. (2013). RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib. Molecular Cancer Therapeutics. 12(6). 865–877. 109 indexed citations

Im, Seock‐Ah, Do‐Youn Oh, Paul Elvin, et al.. (2012). Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer. Molecular Cancer Therapeutics. 12(1). 16–26. 50 indexed citations

Kim, Ji‐Won, Jee Hyun Kim, Seock‐Ah Im, et al.. (2012). ABCB1, FCGR2A, and FCGR3A Polymorphisms in Patients with HER2-Positive Metastatic Breast Cancer Who Were Treated with First-Line Taxane plus Trastuzumab Chemotherapy. Oncology. 83(4). 218–227. 18 indexed citations

10.

Kim, Joong Hyun, Jae Sung Lee, Keon Wook Kang, et al.. (2011). Whole-Body Distribution and Radiation Dosimetry of ⁶⁸ Ga-NOTA-RGD, a Positron Emission Tomography Agent for Angiogenesis Imaging. Cancer Biotherapy and Radiopharmaceuticals. 27(1). 65–71. 47 indexed citations

11.

Yoon, Young‐Kwang, Hwang‐Phill Kim, Sae‐Won Han, et al.. (2009). Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. Molecular Cancer Therapeutics. 8(9). 2526–2536. 62 indexed citations

12.

Lee, Keun‐Wook, Sang Gyun Kim, Hwang‐Phill Kim, et al.. (2008). Enzastaurin, a Protein Kinase Cβ Inhibitor, Suppresses Signaling through the Ribosomal S6 Kinase and Bad Pathways and Induces Apoptosis in Human Gastric Cancer Cells. Cancer Research. 68(6). 1916–1926. 61 indexed citations

13.

Kim, Jin Won, Hwang‐Phill Kim, Seock‐Ah Im, et al.. (2008). The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Letters. 272(2). 296–306. 106 indexed citations

14.

Rhee, Jiyoung, Sae‐Won Han, Do‐Youn Oh, et al.. (2008). The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer. 8(1). 307–307. 108 indexed citations

15.

Han, Sae‐Won, Tae‐You Kim, Yoon Kyung Jeon, et al.. (2006). Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation. Clinical Cancer Research. 12(8). 2538–2544. 196 indexed citations

16.

Kim, Tae‐You, Sooyoung Kim, Eung‐Gyu Kim, et al.. (2006). The Differences of Behavioral and Psychological Symptoms in the Patients of Alzheimer's Disease and Vascular Dementia. Journal of the Korean Neurological Association. 24(5). 458–464. 4 indexed citations

17.

Kim, Tae‐You, et al.. (2006). The Differences of Clinical Features between Alzheimer's Disease and Vascular Dementia According to Progression. Journal of the Korean Neurological Association. 24(4). 337–346.

18.

Lee, Ju‐Hee, Yeonjoo Jung, Jung‐Hyun Park, et al.. (2005). Histone deacetylase inhibitor down-regulates thymidylate synthase expression: Clinical implication of overcoming 5-fluoruracil resistance in human cancer cells. Cancer Research. 65. 424–425. 1 indexed citations

19.

Kim, Tae‐You, et al.. (2004). The Change of Behavioral and Psychological Symptoms according to the Progression of Alzheimer's Disease. Journal of the Korean Neurological Association. 22(1). 34–39. 4 indexed citations

20.

Kim, Tae‐You, et al.. (2003). The Relationship between the Degree of Activity of Daily Living and Clinical Features in Alzheimer's Disease. Journal of the Korean Neurological Association. 21(4). 357–363. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact